Riskpilot← Back to searchSign inGet full accessDrugtestScandinavia AB
ABActiveOrg 5566989090Humlegårdsgatan 4 3 TrTechnical testing and analysis · NACE 7120Est. 20061-4 employees
Revenue 2024
SEK 2,9M
+4% vs 2023
EBITDA margin
-20.6%
-87% vs 2023
Equity ratio
-58.8%
Financial strength
Net profit 2024
SEK -599K
-92% vs 2023
| Revenue | SEK 2,9M | +4% |
| EBITDA | SEK -600K | -87% |
| Net profit | SEK -599K | -92% |
| Total assets | SEK 840K | -37% |
| Equity | SEK -494K | -571% |
| Employees | — | — |
Legal name
DrugtestScandinavia AB
Org number
5566989090
Legal form
Aktiebolag
NACE code
7120 · Technical testing and analysis
Founded
1 mars 2006
Share capital
SEK 100 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget skall bedriva hjälp till större företag i världen att administrera, planera, genomföra och kvalitetssäkra drogtest- program så att de får största möjliga effekt av investerat kapital samt bedriva därmed förenlig verksamhet.
Address
Humlegårdsgatan 4 3 Tr
Email
markus@drugtestscandinavia.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 779 | 1 739 | 2 334 | 2 801 | 2 918 |
| Staff expenses | — | — | — | −1 083 | −1 056 |
| EBITDA | 71 | 134 | 4 | −321 | −600 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 71 | 134 | 4 | −321 | −600 |
| Net financials | −1 | 14 | −54 | 9 | 1 |
| Profit before tax | 70 | 147 | 150 | −312 | −599 |
| Tax | −17 | −31 | −39 | — | — |
| Net profit | 53 | 116 | 111 | −312 | −599 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 481 | 1 706 | 1 917 | 1 336 | 840 |
| Equity | 878 | 994 | 1 106 | 105 | −494 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 430 | 538 | 811 | 1 231 | 1 334 |
| Total debt | 430 | 538 | 811 | 1 231 | 1 334 |
EBITDA margin
-20.6%
This company
15.8%
Market median
-230% vs market
20202024
Equity ratio
-58.8%
This company
38.2%
Market median
-254% vs market
20202024
Return on equity
-59917100.0%
This company
18.4%
Market median
-325636513% vs market
20202024
Net profit margin
-20.5%
This company
8.1%
Market median
-353% vs market
20202024
Asset turnover
3.47×
This company
1.12×
Market median
+210% vs market
20202024
Debt / equity
2.70×
This company
0.62×
Market median
-335% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CG Authorized Recipient of Service | Authorized Recipient of Service | 2025 |
| Former (1) | ||
MT Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Former (1) | ||
| Board of Directors | 2022 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Novir AB
DrugtestScandinavia AB Board members of DrugtestScandinavia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Gustaf Anders Cederström | Authorized Recipient of Service | 0 companies |
| Markus Timosaari | Chief Executive Officer | 0 companies |
| Claudia Maria Jesus Helfrid L Kempe | Board of Directors | 0 companies |
| Patrik Carlos Gerhard Kempe | Board of Directors | 0 companies |
| Alexander Johan Carl Kempe | Chairman | 0 companies |
| Maria Jesus Canal De Kempe | Board of Directors | 0 companies |